CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)
| Status: | Recruiting |
|---|---|
| Conditions: | Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | March 2014 |
| End Date: | October 2017 |
| Contact: | Jun Zhu, MD |
| Email: | zj@bjcancer.org |
| Phone: | +861088196596 |
Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Relapsed and Refractory CD30 Positive Lymphomas
Currently, a majority of lymphomas cannot be cured by standard chemo-radiotherapy. Cluster
of differentiation antigen 30 (CD30) is expressed in many lymphoma subtypes, such as Hodgkin
lymphoma (HL) and anaplastic large cell lymphoma (ALCL). CD30 represents a very attractive
target for chimeric antigen receptor (CAR)-based immune cell therapy. This study will
evaluate a novel 4th generation CD30 CAR engineered with a self-withdrawal mechanism
(FKBP-iCasp9) for both efficacy and safety evaluation in lymphoma patients.
of differentiation antigen 30 (CD30) is expressed in many lymphoma subtypes, such as Hodgkin
lymphoma (HL) and anaplastic large cell lymphoma (ALCL). CD30 represents a very attractive
target for chimeric antigen receptor (CAR)-based immune cell therapy. This study will
evaluate a novel 4th generation CD30 CAR engineered with a self-withdrawal mechanism
(FKBP-iCasp9) for both efficacy and safety evaluation in lymphoma patients.
A large number of lymphoma patients exhaust current treatment options and die from the
disease. Innovative therapy is urgently needed. Chimeric antigen receptor (CAR)-modified T
cells have demonstrated unprecedented successes in treating even late stage cluster of
differentiation antigen 19 (CD19) positive B cell malignancies. Besides CD19 lymphomas, many
lymphomas are CD30 positive and therefore, CD30-CAR T cells may prove to be effective in
treating such patients. We have developed several generations of CD30 CARs. Preclinical
studies have demonstrated effective killing of CD30 target cells. In this study, two
versions of CD30 CARs, both of which are 4th generation CARs with a self-withdrawal
mechanism (FKBP-iCasp9), will be evaluated in CD30 lymphoma patients. The primary goal is
safety assessment including cytokine storm response and any other adverse effects. In
addition, tumor targeting and disease status after treatment will also be evaluated.
disease. Innovative therapy is urgently needed. Chimeric antigen receptor (CAR)-modified T
cells have demonstrated unprecedented successes in treating even late stage cluster of
differentiation antigen 19 (CD19) positive B cell malignancies. Besides CD19 lymphomas, many
lymphomas are CD30 positive and therefore, CD30-CAR T cells may prove to be effective in
treating such patients. We have developed several generations of CD30 CARs. Preclinical
studies have demonstrated effective killing of CD30 target cells. In this study, two
versions of CD30 CARs, both of which are 4th generation CARs with a self-withdrawal
mechanism (FKBP-iCasp9), will be evaluated in CD30 lymphoma patients. The primary goal is
safety assessment including cytokine storm response and any other adverse effects. In
addition, tumor targeting and disease status after treatment will also be evaluated.
Inclusion Criteria:
- Relapsed or refractory CD30(+) lymphoma patients proved by immuno-histochemistry
(IHC) or Flow-cytometry.
- Not eligible for autologous stem-cell transplantation (ASCT) or relapsed after ASCT.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Age≥18.
- Pulse oximetry of > 90% on room air.
- Adequate hepatic function, defined as alanine transaminase (ALT) <3 x upper limit of
normal (ULN), aspartate aminotransferase (AST) <3 x ULN; serum bilirubin and alkaline
phosphatase <2 x ULN.
- Adequate renal function, defined as serum creatinine <2.0mg/dl.
- Adequate heart function with LVEF≥50%
- Hb≥80g/L
- Measurable disease can be identified.
- Life expectancy ≥3 months.
- Sexually active patients must be willing to utilize one of the more effective birth
control methods during the study and for 1 year after the study is concluded. The
male partner should use a condom.
- Patients must sign an informed consent.
Exclusion Criteria:
- Uncontrolled active infection.
- Active infection with hepatitis B virus (HBV), hepatitis C virus (HCV).
- HIV positive
- Pregnant or lactating.
- Currently enrolled in another clinical trial.
- Concurrent use of systemic steroids.
We found this trial at
1
site
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
Click here to add this to my saved trials
